{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:41:24Z","timestamp":1760812884240,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.trim.2022.101713","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T08:06:38Z","timestamp":1662969998000},"page":"101713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients."],"prefix":"10.1016","volume":"75","author":[{"given":"Hideyuki","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriko","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Iwabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Nishina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Matsuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kamijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeji","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhito","family":"Ushiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2022.101713_bb0005","first-page":"1","article-title":"Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine","author":"Gavriatopoulou","year":"2021","journal-title":"Clin. Exp. Med."},{"issue":"10309","key":"10.1016\/j.trim.2022.101713_bb0010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.trim.2022.101713_bb0015","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"author":"W.H. Organization","key":"10.1016\/j.trim.2022.101713_bb0020"},{"author":"C.P.A. Office","key":"10.1016\/j.trim.2022.101713_bb0025"},{"issue":"7","key":"10.1016\/j.trim.2022.101713_bb0030","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(20)30310-7","article-title":"Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study","volume":"21","author":"Yang","year":"2020","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.trim.2022.101713_bb0035","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the international myeloma society data set","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.trim.2022.101713_bb0040","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.trim.2022.101713_bb0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/TP.0000000000003523","article-title":"COVID-19 and solid organ transplantation: a review article","volume":"105","author":"Azzi","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2022.101713_bb0050","series-title":"Environmental Scan of Provincial and Territorial Planning for COVID-19 Vaccination Programs in Canada","first-page":"285","volume":"47(56)","author":"MacDonald","year":"2021"},{"issue":"6","key":"10.1016\/j.trim.2022.101713_bb0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.15585\/mmwr.mm7006e3","article-title":"COVID-19 vaccination intent, perceptions, and reasons for not vaccinating among groups prioritized for early vaccination - United States, September and December 2020","volume":"70","author":"Nguyen","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"5","key":"10.1016\/j.trim.2022.101713_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9050506","article-title":"Strategies for vaccine prioritization and mass dispensing","volume":"9","author":"Lee","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.trim.2022.101713_bb0065","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1038\/s41598-022-06971-5","article-title":"Risk factor targeting for vaccine prioritization during the COVID-19 pandemic","volume":"12","author":"Chapman","year":"2022","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.trim.2022.101713_bb0070","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2188\/jea.JE20210263","article-title":"Rethinking the current older-people-first policy for COVID-19 vaccination in Japan","volume":"31","author":"Matsui","year":"2021","journal-title":"J. Epidemiol."},{"issue":"12","key":"10.1016\/j.trim.2022.101713_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009697","article-title":"Optimal vaccine allocation for COVID-19 in the Netherlands: a data-driven prioritization","volume":"17","author":"Miura","year":"2021","journal-title":"PLoS Comput. Biol."},{"issue":"9","key":"10.1016\/j.trim.2022.101713_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257107","article-title":"Effective vaccine allocation strategies, balancing economy with infection control against COVID-19 in Japan","volume":"16","author":"Sunohara","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.trim.2022.101713_bb0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia","volume":"107","author":"Benjamini","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.trim.2022.101713_bb0090","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/bloodadvances.2021006101","article-title":"Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"6","author":"Jim\u00e9nez","year":"2022","journal-title":"Blood Adv."},{"issue":"17","key":"10.1016\/j.trim.2022.101713_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174480","article-title":"Poor neutralizing antibody responses in 132 patients with CLL, NHL and HL after vaccination against SARS-CoV-2: a prospective study","volume":"13","author":"Terpos","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.trim.2022.101713_bb0100","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.trim.2022.101713_bb0105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12865-021-00458-0","article-title":"Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients","volume":"22","author":"Melin","year":"2021","journal-title":"BMC Immunol."},{"issue":"9","key":"10.1016\/j.trim.2022.101713_bb0110","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1681\/ASN.2021040490","article-title":"Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients","volume":"32","author":"Danthu","year":"2021","journal-title":"J. Am. Soc. Nephrol. JASN"},{"issue":"14","key":"10.1016\/j.trim.2022.101713_bb0115","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150175","article-title":"Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients","volume":"131","author":"Sattler","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"21","key":"10.1016\/j.trim.2022.101713_bb0120","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.trim.2022.101713_bb0125","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13045-021-01190-3","article-title":"Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients","volume":"14","author":"Canti","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.trim.2022.101713_bb0130","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bjh.17918","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients","volume":"196","author":"Shem-Tov","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"14","key":"10.1016\/j.trim.2022.101713_bb0135","article-title":"Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid-organ transplant recipients","volume":"131","author":"Stock","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.trim.2022.101713_bb0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-021-03247-y","article-title":"Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody","volume":"115","author":"Funakoshi","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.trim.2022.101713_bb0145","first-page":"1","article-title":"Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma","author":"Terao","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.trim.2022.101713_bb0150","first-page":"1","article-title":"Antibody response to COVID-19 vaccination in patients with lymphoma","author":"Narita","year":"2022","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.trim.2022.101713_bb0155","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/bjh.18138","article-title":"Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies","volume":"197","author":"Mori","year":"2022","journal-title":"Br. J. Haematol."},{"author":"t.M.o.I.A.a. Communications","key":"10.1016\/j.trim.2022.101713_bb0160"},{"key":"10.1016\/j.trim.2022.101713_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104539","article-title":"Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test","volume":"129","author":"Meschi","year":"2020","journal-title":"J. Clin. virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"author":"M.o.H.L.a. Welfare","key":"10.1016\/j.trim.2022.101713_bb0170"},{"issue":"11","key":"10.1016\/j.trim.2022.101713_bb0175","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1111\/ajt.16185","article-title":"COVID-19 and kidney transplantation: results from the TANGO international transplant consortium","volume":"20","author":"Cravedi","year":"2020","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"issue":"3","key":"10.1016\/j.trim.2022.101713_bb0180","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000547","article-title":"SARS-CoV-2 vaccines in patients with multiple myeloma","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Hemasphere"},{"issue":"8","key":"10.1016\/j.trim.2022.101713_bb0185","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.trim.2022.101713_bb0190","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13045-021-01183-2","article-title":"Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls","volume":"14","author":"Bitoun","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.trim.2022.101713_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10020158","article-title":"The safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation","volume":"10","author":"Watanabe","year":"2022","journal-title":"Vaccines"},{"issue":"12","key":"10.1016\/j.trim.2022.101713_bb0200","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.bbmt.2015.08.010","article-title":"Robust vaccine responses in adult and pediatric cord blood transplantation recipients treated for hematologic malignancies","volume":"21","author":"Shah","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"13","key":"10.1016\/j.trim.2022.101713_bb0205","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients","volume":"385","author":"Hall","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.trim.2022.101713_bb0210","doi-asserted-by":"crossref","first-page":"226","DOI":"10.7326\/M21-3480","article-title":"Neutralization of SARS-CoV-2 variants in transplant recipients after two and three doses of mRNA-1273 vaccine\u202f: secondary analysis of a randomized trial","volume":"175","author":"Kumar","year":"2022","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.trim.2022.101713_bb0215","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamainternmed.2021.7372","article-title":"Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial","volume":"182","author":"Reindl-Schwaighofer","year":"2022","journal-title":"JAMA Intern. Med."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422001873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422001873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:01:32Z","timestamp":1760810492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327422001873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":43,"alternative-id":["S0966327422001873"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2022.101713","relation":{},"ISSN":["0966-3274"],"issn-type":[{"type":"print","value":"0966-3274"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients.","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2022.101713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101713"}}